Global Long-Acting Schizophrenia Drug Market 2022 by Company, Regions, Type and Application, Forecast to 2028
Second-generation antipsychotics are serotonin-dopamine antagonists and are also known as atypical antipsychotics.
The Long-Acting Schizophrenia Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 and Russia-Ukraine War influence, the global Long-Acting Schizophrenia Drug market size was valued at USD million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period.
The Long-Acting Schizophrenia Drug market in the USA. is estimated at USD million in 2022, which currently accounts for a % share in the global market. China, the world`s second largest economy, is estimated at USD million in 2022 and holds a % percent.
Hospital occupied for % of the Long-Acting Schizophrenia Drug global market in 2021, and it is projected to value USD million by 2028, growing at a % CAGR in next six years. In terms of product type, Oral segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Long-Acting Schizophrenia Drug include Johnson & Johnson, Teva, Eli Lilly, Bristol Myers Squibb and AstraZeneca, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Key Features of This Report:
This report provides in-depth analysis of the global Long-Acting Schizophrenia Drug market, and provides market size and CAGR for the history and forecast period (2017-2022, 2023-2028), considering 2021 as the base year.
Main Long-Acting Schizophrenia Drug companies’ industry ranking, revenue, and market share analysis. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This reports profiles key players in the global Long-Acting Schizophrenia Drug market based on the following parameters – headquarters, products portfolio, Long-Acting Schizophrenia Drug revenue and gross margin, recent developments.
Evaluation and forecast the Long-Acting Schizophrenia Drug market size, projected growth trends, and corresponding market share analysis by type, by application and by region. It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
Highlights of the current market scenario, recent information, latest developments, and factors impacting the growth of the market
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Market segmentation
Long-Acting Schizophrenia Drug market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of revenue. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type (2017-2028; USD Million)
Chapter 1, to describe Long-Acting Schizophrenia Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Long-Acting Schizophrenia Drug, with revenue, gross margin and global market share of Long-Acting Schizophrenia Drug from 2019 to 2022.
Chapter 3, the Long-Acting Schizophrenia Drug competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Long-Acting Schizophrenia Drug market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Long-Acting Schizophrenia Drug research findings and conclusion, appendix and data source.
The Long-Acting Schizophrenia Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 and Russia-Ukraine War influence, the global Long-Acting Schizophrenia Drug market size was valued at USD million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period.
The Long-Acting Schizophrenia Drug market in the USA. is estimated at USD million in 2022, which currently accounts for a % share in the global market. China, the world`s second largest economy, is estimated at USD million in 2022 and holds a % percent.
Hospital occupied for % of the Long-Acting Schizophrenia Drug global market in 2021, and it is projected to value USD million by 2028, growing at a % CAGR in next six years. In terms of product type, Oral segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Long-Acting Schizophrenia Drug include Johnson & Johnson, Teva, Eli Lilly, Bristol Myers Squibb and AstraZeneca, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Key Features of This Report:
This report provides in-depth analysis of the global Long-Acting Schizophrenia Drug market, and provides market size and CAGR for the history and forecast period (2017-2022, 2023-2028), considering 2021 as the base year.
Main Long-Acting Schizophrenia Drug companies’ industry ranking, revenue, and market share analysis. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This reports profiles key players in the global Long-Acting Schizophrenia Drug market based on the following parameters – headquarters, products portfolio, Long-Acting Schizophrenia Drug revenue and gross margin, recent developments.
Evaluation and forecast the Long-Acting Schizophrenia Drug market size, projected growth trends, and corresponding market share analysis by type, by application and by region. It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
Highlights of the current market scenario, recent information, latest developments, and factors impacting the growth of the market
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Market segmentation
Long-Acting Schizophrenia Drug market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of revenue. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type (2017-2028; USD Million)
- Oral
- Injection
- Hospital
- Pharmacies
- Other
- Johnson & Johnson
- Teva
- Eli Lilly
- Bristol Myers Squibb
- AstraZeneca
- Sumitomo Dainippon Pharma
- Allergan
- Novartis
- Cardinal Health
- Sun Pharmaceutical Industries
- GlaxoSmithKline
- Sanis Health
- Qilu Pharmaceutical
- Otsuka Pharmaceutical
- Vanda Pharmaceuticals
- H.Lundbeck
- Organon
- Hansoh
- Hengrui
- Nhwa Group
- Yangtze River Pharmaceutical Group
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Australia)
- South America (Brazil, Argentina, Colombia and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa and Rest of Middle East & Africa)
Chapter 1, to describe Long-Acting Schizophrenia Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Long-Acting Schizophrenia Drug, with revenue, gross margin and global market share of Long-Acting Schizophrenia Drug from 2019 to 2022.
Chapter 3, the Long-Acting Schizophrenia Drug competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Long-Acting Schizophrenia Drug market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Long-Acting Schizophrenia Drug research findings and conclusion, appendix and data source.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Long-Acting Schizophrenia Drug
1.2 Classification of Long-Acting Schizophrenia Drug by Type
1.2.1 Overview: Global Long-Acting Schizophrenia Drug Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Long-Acting Schizophrenia Drug Revenue Market Share by Type in 2021
1.2.3 Oral
1.2.4 Injection
1.3 Global Long-Acting Schizophrenia Drug Market by Application
1.3.1 Overview: Global Long-Acting Schizophrenia Drug Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Pharmacies
1.3.4 Other
1.4 Global Long-Acting Schizophrenia Drug Market Size & Forecast
1.5 Global Long-Acting Schizophrenia Drug Market Size and Forecast by Region
1.5.1 Global Long-Acting Schizophrenia Drug Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Long-Acting Schizophrenia Drug Market Size by Region, (2017-2022)
1.5.3 North America Long-Acting Schizophrenia Drug Market Size and Prospect (2017-2028)
1.5.4 Europe Long-Acting Schizophrenia Drug Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Long-Acting Schizophrenia Drug Market Size and Prospect (2017-2028)
1.5.6 South America Long-Acting Schizophrenia Drug Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Long-Acting Schizophrenia Drug Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Long-Acting Schizophrenia Drug Market Drivers
1.6.2 Long-Acting Schizophrenia Drug Market Restraints
1.6.3 Long-Acting Schizophrenia Drug Trends Analysis
2 COMPANY PROFILES
2.1 Johnson & Johnson
2.1.1 Johnson & Johnson Details
2.1.2 Johnson & Johnson Major Business
2.1.3 Johnson & Johnson Long-Acting Schizophrenia Drug Product and Solutions
2.1.4 Johnson & Johnson Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Johnson & Johnson Recent Developments and Future Plans
2.2 Teva
2.2.1 Teva Details
2.2.2 Teva Major Business
2.2.3 Teva Long-Acting Schizophrenia Drug Product and Solutions
2.2.4 Teva Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Teva Recent Developments and Future Plans
2.3 Eli Lilly
2.3.1 Eli Lilly Details
2.3.2 Eli Lilly Major Business
2.3.3 Eli Lilly Long-Acting Schizophrenia Drug Product and Solutions
2.3.4 Eli Lilly Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Eli Lilly Recent Developments and Future Plans
2.4 Bristol Myers Squibb
2.4.1 Bristol Myers Squibb Details
2.4.2 Bristol Myers Squibb Major Business
2.4.3 Bristol Myers Squibb Long-Acting Schizophrenia Drug Product and Solutions
2.4.4 Bristol Myers Squibb Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Bristol Myers Squibb Recent Developments and Future Plans
2.5 AstraZeneca
2.5.1 AstraZeneca Details
2.5.2 AstraZeneca Major Business
2.5.3 AstraZeneca Long-Acting Schizophrenia Drug Product and Solutions
2.5.4 AstraZeneca Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 AstraZeneca Recent Developments and Future Plans
2.6 Sumitomo Dainippon Pharma
2.6.1 Sumitomo Dainippon Pharma Details
2.6.2 Sumitomo Dainippon Pharma Major Business
2.6.3 Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Product and Solutions
2.6.4 Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Sumitomo Dainippon Pharma Recent Developments and Future Plans
2.7 Allergan
2.7.1 Allergan Details
2.7.2 Allergan Major Business
2.7.3 Allergan Long-Acting Schizophrenia Drug Product and Solutions
2.7.4 Allergan Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Allergan Recent Developments and Future Plans
2.8 Novartis
2.8.1 Novartis Details
2.8.2 Novartis Major Business
2.8.3 Novartis Long-Acting Schizophrenia Drug Product and Solutions
2.8.4 Novartis Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Novartis Recent Developments and Future Plans
2.9 Cardinal Health
2.9.1 Cardinal Health Details
2.9.2 Cardinal Health Major Business
2.9.3 Cardinal Health Long-Acting Schizophrenia Drug Product and Solutions
2.9.4 Cardinal Health Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Cardinal Health Recent Developments and Future Plans
2.10 Sun Pharmaceutical Industries
2.10.1 Sun Pharmaceutical Industries Details
2.10.2 Sun Pharmaceutical Industries Major Business
2.10.3 Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Product and Solutions
2.10.4 Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Sun Pharmaceutical Industries Recent Developments and Future Plans
2.11 GlaxoSmithKline
2.11.1 GlaxoSmithKline Details
2.11.2 GlaxoSmithKline Major Business
2.11.3 GlaxoSmithKline Long-Acting Schizophrenia Drug Product and Solutions
2.11.4 GlaxoSmithKline Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 GlaxoSmithKline Recent Developments and Future Plans
2.12 Sanis Health
2.12.1 Sanis Health Details
2.12.2 Sanis Health Major Business
2.12.3 Sanis Health Long-Acting Schizophrenia Drug Product and Solutions
2.12.4 Sanis Health Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Sanis Health Recent Developments and Future Plans
2.13 Qilu Pharmaceutical
2.13.1 Qilu Pharmaceutical Details
2.13.2 Qilu Pharmaceutical Major Business
2.13.3 Qilu Pharmaceutical Long-Acting Schizophrenia Drug Product and Solutions
2.13.4 Qilu Pharmaceutical Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 Qilu Pharmaceutical Recent Developments and Future Plans
2.14 Otsuka Pharmaceutical
2.14.1 Otsuka Pharmaceutical Details
2.14.2 Otsuka Pharmaceutical Major Business
2.14.3 Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Product and Solutions
2.14.4 Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14.5 Otsuka Pharmaceutical Recent Developments and Future Plans
2.15 Vanda Pharmaceuticals
2.15.1 Vanda Pharmaceuticals Details
2.15.2 Vanda Pharmaceuticals Major Business
2.15.3 Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Product and Solutions
2.15.4 Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15.5 Vanda Pharmaceuticals Recent Developments and Future Plans
2.16 H.Lundbeck
2.16.1 H.Lundbeck Details
2.16.2 H.Lundbeck Major Business
2.16.3 H.Lundbeck Long-Acting Schizophrenia Drug Product and Solutions
2.16.4 H.Lundbeck Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16.5 H.Lundbeck Recent Developments and Future Plans
2.17 Organon
2.17.1 Organon Details
2.17.2 Organon Major Business
2.17.3 Organon Long-Acting Schizophrenia Drug Product and Solutions
2.17.4 Organon Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17.5 Organon Recent Developments and Future Plans
2.18 Hansoh
2.18.1 Hansoh Details
2.18.2 Hansoh Major Business
2.18.3 Hansoh Long-Acting Schizophrenia Drug Product and Solutions
2.18.4 Hansoh Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18.5 Hansoh Recent Developments and Future Plans
2.19 Hengrui
2.19.1 Hengrui Details
2.19.2 Hengrui Major Business
2.19.3 Hengrui Long-Acting Schizophrenia Drug Product and Solutions
2.19.4 Hengrui Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.19.5 Hengrui Recent Developments and Future Plans
2.20 Nhwa Group
2.20.1 Nhwa Group Details
2.20.2 Nhwa Group Major Business
2.20.3 Nhwa Group Long-Acting Schizophrenia Drug Product and Solutions
2.20.4 Nhwa Group Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.20.5 Nhwa Group Recent Developments and Future Plans
2.21 Yangtze River Pharmaceutical Group
2.21.1 Yangtze River Pharmaceutical Group Details
2.21.2 Yangtze River Pharmaceutical Group Major Business
2.21.3 Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Product and Solutions
2.21.4 Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.21.5 Yangtze River Pharmaceutical Group Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Long-Acting Schizophrenia Drug Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Long-Acting Schizophrenia Drug Players Market Share in 2021
3.2.2 Top 10 Long-Acting Schizophrenia Drug Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Long-Acting Schizophrenia Drug Players Head Office, Products and Services Provided
3.4 Long-Acting Schizophrenia Drug Mergers & Acquisitions
3.5 Long-Acting Schizophrenia Drug New Entrants and Expansion Plans
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Long-Acting Schizophrenia Drug Revenue and Market Share by Type (2017-2022)
4.2 Global Long-Acting Schizophrenia Drug Market Forecast by Type (2023-2028)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Long-Acting Schizophrenia Drug Revenue Market Share by Application (2017-2022)
5.2 Global Long-Acting Schizophrenia Drug Market Forecast by Application (2023-2028)
6 NORTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
6.1 North America Long-Acting Schizophrenia Drug Revenue by Type (2017-2028)
6.2 North America Long-Acting Schizophrenia Drug Revenue by Application (2017-2028)
6.3 North America Long-Acting Schizophrenia Drug Market Size by Country
6.3.1 North America Long-Acting Schizophrenia Drug Revenue by Country (2017-2028)
6.3.2 United States Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
6.3.3 Canada Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
6.3.4 Mexico Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
7 EUROPE BY COUNTRY, BY TYPE, AND BY APPLICATION
7.1 Europe Long-Acting Schizophrenia Drug Revenue by Type (2017-2028)
7.2 Europe Long-Acting Schizophrenia Drug Revenue by Application (2017-2028)
7.3 Europe Long-Acting Schizophrenia Drug Market Size by Country
7.3.1 Europe Long-Acting Schizophrenia Drug Revenue by Country (2017-2028)
7.3.2 Germany Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
7.3.3 France Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
7.3.5 Russia Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
7.3.6 Italy Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
8 ASIA-PACIFIC BY REGION, BY TYPE, AND BY APPLICATION
8.1 Asia-Pacific Long-Acting Schizophrenia Drug Revenue by Type (2017-2028)
8.2 Asia-Pacific Long-Acting Schizophrenia Drug Revenue by Application (2017-2028)
8.3 Asia-Pacific Long-Acting Schizophrenia Drug Market Size by Region
8.3.1 Asia-Pacific Long-Acting Schizophrenia Drug Revenue by Region (2017-2028)
8.3.2 China Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
8.3.3 Japan Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
8.3.4 South Korea Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
8.3.5 India Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
8.3.7 Australia Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
9 SOUTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
9.1 South America Long-Acting Schizophrenia Drug Revenue by Type (2017-2028)
9.2 South America Long-Acting Schizophrenia Drug Revenue by Application (2017-2028)
9.3 South America Long-Acting Schizophrenia Drug Market Size by Country
9.3.1 South America Long-Acting Schizophrenia Drug Revenue by Country (2017-2028)
9.3.2 Brazil Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
9.3.3 Argentina Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
10 MIDDLE EAST & AFRICA BY COUNTRY, BY TYPE, AND BY APPLICATION
10.1 Middle East & Africa Long-Acting Schizophrenia Drug Revenue by Type (2017-2028)
10.2 Middle East & Africa Long-Acting Schizophrenia Drug Revenue by Application (2017-2028)
10.3 Middle East & Africa Long-Acting Schizophrenia Drug Market Size by Country
10.3.1 Middle East & Africa Long-Acting Schizophrenia Drug Revenue by Country (2017-2028)
10.3.2 Turkey Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
10.3.4 UAE Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Product Overview and Scope of Long-Acting Schizophrenia Drug
1.2 Classification of Long-Acting Schizophrenia Drug by Type
1.2.1 Overview: Global Long-Acting Schizophrenia Drug Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Long-Acting Schizophrenia Drug Revenue Market Share by Type in 2021
1.2.3 Oral
1.2.4 Injection
1.3 Global Long-Acting Schizophrenia Drug Market by Application
1.3.1 Overview: Global Long-Acting Schizophrenia Drug Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Pharmacies
1.3.4 Other
1.4 Global Long-Acting Schizophrenia Drug Market Size & Forecast
1.5 Global Long-Acting Schizophrenia Drug Market Size and Forecast by Region
1.5.1 Global Long-Acting Schizophrenia Drug Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Long-Acting Schizophrenia Drug Market Size by Region, (2017-2022)
1.5.3 North America Long-Acting Schizophrenia Drug Market Size and Prospect (2017-2028)
1.5.4 Europe Long-Acting Schizophrenia Drug Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Long-Acting Schizophrenia Drug Market Size and Prospect (2017-2028)
1.5.6 South America Long-Acting Schizophrenia Drug Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Long-Acting Schizophrenia Drug Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Long-Acting Schizophrenia Drug Market Drivers
1.6.2 Long-Acting Schizophrenia Drug Market Restraints
1.6.3 Long-Acting Schizophrenia Drug Trends Analysis
2 COMPANY PROFILES
2.1 Johnson & Johnson
2.1.1 Johnson & Johnson Details
2.1.2 Johnson & Johnson Major Business
2.1.3 Johnson & Johnson Long-Acting Schizophrenia Drug Product and Solutions
2.1.4 Johnson & Johnson Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Johnson & Johnson Recent Developments and Future Plans
2.2 Teva
2.2.1 Teva Details
2.2.2 Teva Major Business
2.2.3 Teva Long-Acting Schizophrenia Drug Product and Solutions
2.2.4 Teva Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Teva Recent Developments and Future Plans
2.3 Eli Lilly
2.3.1 Eli Lilly Details
2.3.2 Eli Lilly Major Business
2.3.3 Eli Lilly Long-Acting Schizophrenia Drug Product and Solutions
2.3.4 Eli Lilly Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Eli Lilly Recent Developments and Future Plans
2.4 Bristol Myers Squibb
2.4.1 Bristol Myers Squibb Details
2.4.2 Bristol Myers Squibb Major Business
2.4.3 Bristol Myers Squibb Long-Acting Schizophrenia Drug Product and Solutions
2.4.4 Bristol Myers Squibb Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Bristol Myers Squibb Recent Developments and Future Plans
2.5 AstraZeneca
2.5.1 AstraZeneca Details
2.5.2 AstraZeneca Major Business
2.5.3 AstraZeneca Long-Acting Schizophrenia Drug Product and Solutions
2.5.4 AstraZeneca Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 AstraZeneca Recent Developments and Future Plans
2.6 Sumitomo Dainippon Pharma
2.6.1 Sumitomo Dainippon Pharma Details
2.6.2 Sumitomo Dainippon Pharma Major Business
2.6.3 Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Product and Solutions
2.6.4 Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Sumitomo Dainippon Pharma Recent Developments and Future Plans
2.7 Allergan
2.7.1 Allergan Details
2.7.2 Allergan Major Business
2.7.3 Allergan Long-Acting Schizophrenia Drug Product and Solutions
2.7.4 Allergan Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Allergan Recent Developments and Future Plans
2.8 Novartis
2.8.1 Novartis Details
2.8.2 Novartis Major Business
2.8.3 Novartis Long-Acting Schizophrenia Drug Product and Solutions
2.8.4 Novartis Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Novartis Recent Developments and Future Plans
2.9 Cardinal Health
2.9.1 Cardinal Health Details
2.9.2 Cardinal Health Major Business
2.9.3 Cardinal Health Long-Acting Schizophrenia Drug Product and Solutions
2.9.4 Cardinal Health Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Cardinal Health Recent Developments and Future Plans
2.10 Sun Pharmaceutical Industries
2.10.1 Sun Pharmaceutical Industries Details
2.10.2 Sun Pharmaceutical Industries Major Business
2.10.3 Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Product and Solutions
2.10.4 Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Sun Pharmaceutical Industries Recent Developments and Future Plans
2.11 GlaxoSmithKline
2.11.1 GlaxoSmithKline Details
2.11.2 GlaxoSmithKline Major Business
2.11.3 GlaxoSmithKline Long-Acting Schizophrenia Drug Product and Solutions
2.11.4 GlaxoSmithKline Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 GlaxoSmithKline Recent Developments and Future Plans
2.12 Sanis Health
2.12.1 Sanis Health Details
2.12.2 Sanis Health Major Business
2.12.3 Sanis Health Long-Acting Schizophrenia Drug Product and Solutions
2.12.4 Sanis Health Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Sanis Health Recent Developments and Future Plans
2.13 Qilu Pharmaceutical
2.13.1 Qilu Pharmaceutical Details
2.13.2 Qilu Pharmaceutical Major Business
2.13.3 Qilu Pharmaceutical Long-Acting Schizophrenia Drug Product and Solutions
2.13.4 Qilu Pharmaceutical Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 Qilu Pharmaceutical Recent Developments and Future Plans
2.14 Otsuka Pharmaceutical
2.14.1 Otsuka Pharmaceutical Details
2.14.2 Otsuka Pharmaceutical Major Business
2.14.3 Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Product and Solutions
2.14.4 Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14.5 Otsuka Pharmaceutical Recent Developments and Future Plans
2.15 Vanda Pharmaceuticals
2.15.1 Vanda Pharmaceuticals Details
2.15.2 Vanda Pharmaceuticals Major Business
2.15.3 Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Product and Solutions
2.15.4 Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15.5 Vanda Pharmaceuticals Recent Developments and Future Plans
2.16 H.Lundbeck
2.16.1 H.Lundbeck Details
2.16.2 H.Lundbeck Major Business
2.16.3 H.Lundbeck Long-Acting Schizophrenia Drug Product and Solutions
2.16.4 H.Lundbeck Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16.5 H.Lundbeck Recent Developments and Future Plans
2.17 Organon
2.17.1 Organon Details
2.17.2 Organon Major Business
2.17.3 Organon Long-Acting Schizophrenia Drug Product and Solutions
2.17.4 Organon Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17.5 Organon Recent Developments and Future Plans
2.18 Hansoh
2.18.1 Hansoh Details
2.18.2 Hansoh Major Business
2.18.3 Hansoh Long-Acting Schizophrenia Drug Product and Solutions
2.18.4 Hansoh Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18.5 Hansoh Recent Developments and Future Plans
2.19 Hengrui
2.19.1 Hengrui Details
2.19.2 Hengrui Major Business
2.19.3 Hengrui Long-Acting Schizophrenia Drug Product and Solutions
2.19.4 Hengrui Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.19.5 Hengrui Recent Developments and Future Plans
2.20 Nhwa Group
2.20.1 Nhwa Group Details
2.20.2 Nhwa Group Major Business
2.20.3 Nhwa Group Long-Acting Schizophrenia Drug Product and Solutions
2.20.4 Nhwa Group Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.20.5 Nhwa Group Recent Developments and Future Plans
2.21 Yangtze River Pharmaceutical Group
2.21.1 Yangtze River Pharmaceutical Group Details
2.21.2 Yangtze River Pharmaceutical Group Major Business
2.21.3 Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Product and Solutions
2.21.4 Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.21.5 Yangtze River Pharmaceutical Group Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Long-Acting Schizophrenia Drug Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Long-Acting Schizophrenia Drug Players Market Share in 2021
3.2.2 Top 10 Long-Acting Schizophrenia Drug Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Long-Acting Schizophrenia Drug Players Head Office, Products and Services Provided
3.4 Long-Acting Schizophrenia Drug Mergers & Acquisitions
3.5 Long-Acting Schizophrenia Drug New Entrants and Expansion Plans
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Long-Acting Schizophrenia Drug Revenue and Market Share by Type (2017-2022)
4.2 Global Long-Acting Schizophrenia Drug Market Forecast by Type (2023-2028)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Long-Acting Schizophrenia Drug Revenue Market Share by Application (2017-2022)
5.2 Global Long-Acting Schizophrenia Drug Market Forecast by Application (2023-2028)
6 NORTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
6.1 North America Long-Acting Schizophrenia Drug Revenue by Type (2017-2028)
6.2 North America Long-Acting Schizophrenia Drug Revenue by Application (2017-2028)
6.3 North America Long-Acting Schizophrenia Drug Market Size by Country
6.3.1 North America Long-Acting Schizophrenia Drug Revenue by Country (2017-2028)
6.3.2 United States Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
6.3.3 Canada Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
6.3.4 Mexico Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
7 EUROPE BY COUNTRY, BY TYPE, AND BY APPLICATION
7.1 Europe Long-Acting Schizophrenia Drug Revenue by Type (2017-2028)
7.2 Europe Long-Acting Schizophrenia Drug Revenue by Application (2017-2028)
7.3 Europe Long-Acting Schizophrenia Drug Market Size by Country
7.3.1 Europe Long-Acting Schizophrenia Drug Revenue by Country (2017-2028)
7.3.2 Germany Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
7.3.3 France Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
7.3.5 Russia Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
7.3.6 Italy Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
8 ASIA-PACIFIC BY REGION, BY TYPE, AND BY APPLICATION
8.1 Asia-Pacific Long-Acting Schizophrenia Drug Revenue by Type (2017-2028)
8.2 Asia-Pacific Long-Acting Schizophrenia Drug Revenue by Application (2017-2028)
8.3 Asia-Pacific Long-Acting Schizophrenia Drug Market Size by Region
8.3.1 Asia-Pacific Long-Acting Schizophrenia Drug Revenue by Region (2017-2028)
8.3.2 China Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
8.3.3 Japan Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
8.3.4 South Korea Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
8.3.5 India Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
8.3.7 Australia Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
9 SOUTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
9.1 South America Long-Acting Schizophrenia Drug Revenue by Type (2017-2028)
9.2 South America Long-Acting Schizophrenia Drug Revenue by Application (2017-2028)
9.3 South America Long-Acting Schizophrenia Drug Market Size by Country
9.3.1 South America Long-Acting Schizophrenia Drug Revenue by Country (2017-2028)
9.3.2 Brazil Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
9.3.3 Argentina Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
10 MIDDLE EAST & AFRICA BY COUNTRY, BY TYPE, AND BY APPLICATION
10.1 Middle East & Africa Long-Acting Schizophrenia Drug Revenue by Type (2017-2028)
10.2 Middle East & Africa Long-Acting Schizophrenia Drug Revenue by Application (2017-2028)
10.3 Middle East & Africa Long-Acting Schizophrenia Drug Market Size by Country
10.3.1 Middle East & Africa Long-Acting Schizophrenia Drug Revenue by Country (2017-2028)
10.3.2 Turkey Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
10.3.4 UAE Long-Acting Schizophrenia Drug Market Size and Forecast (2017-2028)
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. Global Long-Acting Schizophrenia Drug Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Long-Acting Schizophrenia Drug Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Long-Acting Schizophrenia Drug Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Long-Acting Schizophrenia Drug Revenue (USD Million) by Region (2017-2022)
Table 5. Global Long-Acting Schizophrenia Drug Revenue Market Share by Region (2023-2028)
Table 6. Johnson & Johnson Corporate Information, Head Office, and Major Competitors
Table 7. Johnson & Johnson Major Business
Table 8. Johnson & Johnson Long-Acting Schizophrenia Drug Product and Solutions
Table 9. Johnson & Johnson Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Teva Corporate Information, Head Office, and Major Competitors
Table 11. Teva Major Business
Table 12. Teva Long-Acting Schizophrenia Drug Product and Solutions
Table 13. Teva Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Eli Lilly Corporate Information, Head Office, and Major Competitors
Table 15. Eli Lilly Major Business
Table 16. Eli Lilly Long-Acting Schizophrenia Drug Product and Solutions
Table 17. Eli Lilly Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Bristol Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 19. Bristol Myers Squibb Major Business
Table 20. Bristol Myers Squibb Long-Acting Schizophrenia Drug Product and Solutions
Table 21. Bristol Myers Squibb Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 23. AstraZeneca Major Business
Table 24. AstraZeneca Long-Acting Schizophrenia Drug Product and Solutions
Table 25. AstraZeneca Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Sumitomo Dainippon Pharma Corporate Information, Head Office, and Major Competitors
Table 27. Sumitomo Dainippon Pharma Major Business
Table 28. Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Product and Solutions
Table 29. Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Allergan Corporate Information, Head Office, and Major Competitors
Table 31. Allergan Major Business
Table 32. Allergan Long-Acting Schizophrenia Drug Product and Solutions
Table 33. Allergan Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Novartis Corporate Information, Head Office, and Major Competitors
Table 35. Novartis Major Business
Table 36. Novartis Long-Acting Schizophrenia Drug Product and Solutions
Table 37. Novartis Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Cardinal Health Corporate Information, Head Office, and Major Competitors
Table 39. Cardinal Health Major Business
Table 40. Cardinal Health Long-Acting Schizophrenia Drug Product and Solutions
Table 41. Cardinal Health Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Sun Pharmaceutical Industries Corporate Information, Head Office, and Major Competitors
Table 43. Sun Pharmaceutical Industries Major Business
Table 44. Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Product and Solutions
Table 45. Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 47. GlaxoSmithKline Major Business
Table 48. GlaxoSmithKline Long-Acting Schizophrenia Drug Product and Solutions
Table 49. GlaxoSmithKline Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Sanis Health Corporate Information, Head Office, and Major Competitors
Table 51. Sanis Health Major Business
Table 52. Sanis Health Long-Acting Schizophrenia Drug Product and Solutions
Table 53. Sanis Health Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. Qilu Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 55. Qilu Pharmaceutical Major Business
Table 56. Qilu Pharmaceutical Long-Acting Schizophrenia Drug Product and Solutions
Table 57. Qilu Pharmaceutical Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. Otsuka Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 59. Otsuka Pharmaceutical Major Business
Table 60. Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Product and Solutions
Table 61. Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 62. Vanda Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 63. Vanda Pharmaceuticals Major Business
Table 64. Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Product and Solutions
Table 65. Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 66. H.Lundbeck Corporate Information, Head Office, and Major Competitors
Table 67. H.Lundbeck Major Business
Table 68. H.Lundbeck Long-Acting Schizophrenia Drug Product and Solutions
Table 69. H.Lundbeck Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 70. Organon Corporate Information, Head Office, and Major Competitors
Table 71. Organon Major Business
Table 72. Organon Long-Acting Schizophrenia Drug Product and Solutions
Table 73. Organon Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 74. Hansoh Corporate Information, Head Office, and Major Competitors
Table 75. Hansoh Major Business
Table 76. Hansoh Long-Acting Schizophrenia Drug Product and Solutions
Table 77. Hansoh Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 78. Hengrui Corporate Information, Head Office, and Major Competitors
Table 79. Hengrui Major Business
Table 80. Hengrui Long-Acting Schizophrenia Drug Product and Solutions
Table 81. Hengrui Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 82. Nhwa Group Corporate Information, Head Office, and Major Competitors
Table 83. Nhwa Group Major Business
Table 84. Nhwa Group Long-Acting Schizophrenia Drug Product and Solutions
Table 85. Nhwa Group Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 86. Yangtze River Pharmaceutical Group Corporate Information, Head Office, and Major Competitors
Table 87. Yangtze River Pharmaceutical Group Major Business
Table 88. Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Product and Solutions
Table 89. Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 90. Global Long-Acting Schizophrenia Drug Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 91. Global Long-Acting Schizophrenia Drug Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 92. Breakdown of Long-Acting Schizophrenia Drug by Company Type (Tier 1, Tier 2 and Tier 3)
Table 93. Long-Acting Schizophrenia Drug Players Head Office, Products and Services Provided
Table 94. Long-Acting Schizophrenia Drug Mergers & Acquisitions in the Past Five Years
Table 95. Long-Acting Schizophrenia Drug New Entrants and Expansion Plans
Table 96. Global Long-Acting Schizophrenia Drug Revenue (USD Million) by Type (2017-2022)
Table 97. Global Long-Acting Schizophrenia Drug Revenue Share by Type (2017-2022)
Table 98. Global Long-Acting Schizophrenia Drug Revenue Forecast by Type (2023-2028)
Table 99. Global Long-Acting Schizophrenia Drug Revenue by Application (2017-2022)
Table 100. Global Long-Acting Schizophrenia Drug Revenue Forecast by Application (2023-2028)
Table 101. North America Long-Acting Schizophrenia Drug Revenue by Type (2017-2022) & (USD Million)
Table 102. North America Long-Acting Schizophrenia Drug Revenue by Type (2023-2028) & (USD Million)
Table 103. North America Long-Acting Schizophrenia Drug Revenue by Application (2017-2022) & (USD Million)
Table 104. North America Long-Acting Schizophrenia Drug Revenue by Application (2023-2028) & (USD Million)
Table 105. North America Long-Acting Schizophrenia Drug Revenue by Country (2017-2022) & (USD Million)
Table 106. North America Long-Acting Schizophrenia Drug Revenue by Country (2023-2028) & (USD Million)
Table 107. Europe Long-Acting Schizophrenia Drug Revenue by Type (2017-2022) & (USD Million)
Table 108. Europe Long-Acting Schizophrenia Drug Revenue by Type (2023-2028) & (USD Million)
Table 109. Europe Long-Acting Schizophrenia Drug Revenue by Application (2017-2022) & (USD Million)
Table 110. Europe Long-Acting Schizophrenia Drug Revenue by Application (2023-2028) & (USD Million)
Table 111. Europe Long-Acting Schizophrenia Drug Revenue by Country (2017-2022) & (USD Million)
Table 112. Europe Long-Acting Schizophrenia Drug Revenue by Country (2023-2028) & (USD Million)
Table 113. Asia-Pacific Long-Acting Schizophrenia Drug Revenue by Type (2017-2022) & (USD Million)
Table 114. Asia-Pacific Long-Acting Schizophrenia Drug Revenue by Type (2023-2028) & (USD Million)
Table 115. Asia-Pacific Long-Acting Schizophrenia Drug Revenue by Application (2017-2022) & (USD Million)
Table 116. Asia-Pacific Long-Acting Schizophrenia Drug Revenue by Application (2023-2028) & (USD Million)
Table 117. Asia-Pacific Long-Acting Schizophrenia Drug Revenue by Region (2017-2022) & (USD Million)
Table 118. Asia-Pacific Long-Acting Schizophrenia Drug Revenue by Region (2023-2028) & (USD Million)
Table 119. South America Long-Acting Schizophrenia Drug Revenue by Type (2017-2022) & (USD Million)
Table 120. South America Long-Acting Schizophrenia Drug Revenue by Type (2023-2028) & (USD Million)
Table 121. South America Long-Acting Schizophrenia Drug Revenue by Application (2017-2022) & (USD Million)
Table 122. South America Long-Acting Schizophrenia Drug Revenue by Application (2023-2028) & (USD Million)
Table 123. South America Long-Acting Schizophrenia Drug Revenue by Country (2017-2022) & (USD Million)
Table 124. South America Long-Acting Schizophrenia Drug Revenue by Country (2023-2028) & (USD Million)
Table 125. Middle East & Africa Long-Acting Schizophrenia Drug Revenue by Type (2017-2022) & (USD Million)
Table 126. Middle East & Africa Long-Acting Schizophrenia Drug Revenue by Type (2023-2028) & (USD Million)
Table 127. Middle East & Africa Long-Acting Schizophrenia Drug Revenue by Application (2017-2022) & (USD Million)
Table 128. Middle East & Africa Long-Acting Schizophrenia Drug Revenue by Application (2023-2028) & (USD Million)
Table 129. Middle East & Africa Long-Acting Schizophrenia Drug Revenue by Country (2017-2022) & (USD Million)
Table 130. Middle East & Africa Long-Acting Schizophrenia Drug Revenue by Country (2023-2028) & (USD Million)
Table 1. Global Long-Acting Schizophrenia Drug Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Long-Acting Schizophrenia Drug Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Long-Acting Schizophrenia Drug Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Long-Acting Schizophrenia Drug Revenue (USD Million) by Region (2017-2022)
Table 5. Global Long-Acting Schizophrenia Drug Revenue Market Share by Region (2023-2028)
Table 6. Johnson & Johnson Corporate Information, Head Office, and Major Competitors
Table 7. Johnson & Johnson Major Business
Table 8. Johnson & Johnson Long-Acting Schizophrenia Drug Product and Solutions
Table 9. Johnson & Johnson Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Teva Corporate Information, Head Office, and Major Competitors
Table 11. Teva Major Business
Table 12. Teva Long-Acting Schizophrenia Drug Product and Solutions
Table 13. Teva Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Eli Lilly Corporate Information, Head Office, and Major Competitors
Table 15. Eli Lilly Major Business
Table 16. Eli Lilly Long-Acting Schizophrenia Drug Product and Solutions
Table 17. Eli Lilly Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Bristol Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 19. Bristol Myers Squibb Major Business
Table 20. Bristol Myers Squibb Long-Acting Schizophrenia Drug Product and Solutions
Table 21. Bristol Myers Squibb Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 23. AstraZeneca Major Business
Table 24. AstraZeneca Long-Acting Schizophrenia Drug Product and Solutions
Table 25. AstraZeneca Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Sumitomo Dainippon Pharma Corporate Information, Head Office, and Major Competitors
Table 27. Sumitomo Dainippon Pharma Major Business
Table 28. Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Product and Solutions
Table 29. Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Allergan Corporate Information, Head Office, and Major Competitors
Table 31. Allergan Major Business
Table 32. Allergan Long-Acting Schizophrenia Drug Product and Solutions
Table 33. Allergan Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Novartis Corporate Information, Head Office, and Major Competitors
Table 35. Novartis Major Business
Table 36. Novartis Long-Acting Schizophrenia Drug Product and Solutions
Table 37. Novartis Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Cardinal Health Corporate Information, Head Office, and Major Competitors
Table 39. Cardinal Health Major Business
Table 40. Cardinal Health Long-Acting Schizophrenia Drug Product and Solutions
Table 41. Cardinal Health Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Sun Pharmaceutical Industries Corporate Information, Head Office, and Major Competitors
Table 43. Sun Pharmaceutical Industries Major Business
Table 44. Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Product and Solutions
Table 45. Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 47. GlaxoSmithKline Major Business
Table 48. GlaxoSmithKline Long-Acting Schizophrenia Drug Product and Solutions
Table 49. GlaxoSmithKline Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Sanis Health Corporate Information, Head Office, and Major Competitors
Table 51. Sanis Health Major Business
Table 52. Sanis Health Long-Acting Schizophrenia Drug Product and Solutions
Table 53. Sanis Health Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. Qilu Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 55. Qilu Pharmaceutical Major Business
Table 56. Qilu Pharmaceutical Long-Acting Schizophrenia Drug Product and Solutions
Table 57. Qilu Pharmaceutical Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. Otsuka Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 59. Otsuka Pharmaceutical Major Business
Table 60. Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Product and Solutions
Table 61. Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 62. Vanda Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 63. Vanda Pharmaceuticals Major Business
Table 64. Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Product and Solutions
Table 65. Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 66. H.Lundbeck Corporate Information, Head Office, and Major Competitors
Table 67. H.Lundbeck Major Business
Table 68. H.Lundbeck Long-Acting Schizophrenia Drug Product and Solutions
Table 69. H.Lundbeck Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 70. Organon Corporate Information, Head Office, and Major Competitors
Table 71. Organon Major Business
Table 72. Organon Long-Acting Schizophrenia Drug Product and Solutions
Table 73. Organon Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 74. Hansoh Corporate Information, Head Office, and Major Competitors
Table 75. Hansoh Major Business
Table 76. Hansoh Long-Acting Schizophrenia Drug Product and Solutions
Table 77. Hansoh Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 78. Hengrui Corporate Information, Head Office, and Major Competitors
Table 79. Hengrui Major Business
Table 80. Hengrui Long-Acting Schizophrenia Drug Product and Solutions
Table 81. Hengrui Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 82. Nhwa Group Corporate Information, Head Office, and Major Competitors
Table 83. Nhwa Group Major Business
Table 84. Nhwa Group Long-Acting Schizophrenia Drug Product and Solutions
Table 85. Nhwa Group Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 86. Yangtze River Pharmaceutical Group Corporate Information, Head Office, and Major Competitors
Table 87. Yangtze River Pharmaceutical Group Major Business
Table 88. Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Product and Solutions
Table 89. Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 90. Global Long-Acting Schizophrenia Drug Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 91. Global Long-Acting Schizophrenia Drug Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 92. Breakdown of Long-Acting Schizophrenia Drug by Company Type (Tier 1, Tier 2 and Tier 3)
Table 93. Long-Acting Schizophrenia Drug Players Head Office, Products and Services Provided
Table 94. Long-Acting Schizophrenia Drug Mergers & Acquisitions in the Past Five Years
Table 95. Long-Acting Schizophrenia Drug New Entrants and Expansion Plans
Table 96. Global Long-Acting Schizophrenia Drug Revenue (USD Million) by Type (2017-2022)
Table 97. Global Long-Acting Schizophrenia Drug Revenue Share by Type (2017-2022)
Table 98. Global Long-Acting Schizophrenia Drug Revenue Forecast by Type (2023-2028)
Table 99. Global Long-Acting Schizophrenia Drug Revenue by Application (2017-2022)
Table 100. Global Long-Acting Schizophrenia Drug Revenue Forecast by Application (2023-2028)
Table 101. North America Long-Acting Schizophrenia Drug Revenue by Type (2017-2022) & (USD Million)
Table 102. North America Long-Acting Schizophrenia Drug Revenue by Type (2023-2028) & (USD Million)
Table 103. North America Long-Acting Schizophrenia Drug Revenue by Application (2017-2022) & (USD Million)
Table 104. North America Long-Acting Schizophrenia Drug Revenue by Application (2023-2028) & (USD Million)
Table 105. North America Long-Acting Schizophrenia Drug Revenue by Country (2017-2022) & (USD Million)
Table 106. North America Long-Acting Schizophrenia Drug Revenue by Country (2023-2028) & (USD Million)
Table 107. Europe Long-Acting Schizophrenia Drug Revenue by Type (2017-2022) & (USD Million)
Table 108. Europe Long-Acting Schizophrenia Drug Revenue by Type (2023-2028) & (USD Million)
Table 109. Europe Long-Acting Schizophrenia Drug Revenue by Application (2017-2022) & (USD Million)
Table 110. Europe Long-Acting Schizophrenia Drug Revenue by Application (2023-2028) & (USD Million)
Table 111. Europe Long-Acting Schizophrenia Drug Revenue by Country (2017-2022) & (USD Million)
Table 112. Europe Long-Acting Schizophrenia Drug Revenue by Country (2023-2028) & (USD Million)
Table 113. Asia-Pacific Long-Acting Schizophrenia Drug Revenue by Type (2017-2022) & (USD Million)
Table 114. Asia-Pacific Long-Acting Schizophrenia Drug Revenue by Type (2023-2028) & (USD Million)
Table 115. Asia-Pacific Long-Acting Schizophrenia Drug Revenue by Application (2017-2022) & (USD Million)
Table 116. Asia-Pacific Long-Acting Schizophrenia Drug Revenue by Application (2023-2028) & (USD Million)
Table 117. Asia-Pacific Long-Acting Schizophrenia Drug Revenue by Region (2017-2022) & (USD Million)
Table 118. Asia-Pacific Long-Acting Schizophrenia Drug Revenue by Region (2023-2028) & (USD Million)
Table 119. South America Long-Acting Schizophrenia Drug Revenue by Type (2017-2022) & (USD Million)
Table 120. South America Long-Acting Schizophrenia Drug Revenue by Type (2023-2028) & (USD Million)
Table 121. South America Long-Acting Schizophrenia Drug Revenue by Application (2017-2022) & (USD Million)
Table 122. South America Long-Acting Schizophrenia Drug Revenue by Application (2023-2028) & (USD Million)
Table 123. South America Long-Acting Schizophrenia Drug Revenue by Country (2017-2022) & (USD Million)
Table 124. South America Long-Acting Schizophrenia Drug Revenue by Country (2023-2028) & (USD Million)
Table 125. Middle East & Africa Long-Acting Schizophrenia Drug Revenue by Type (2017-2022) & (USD Million)
Table 126. Middle East & Africa Long-Acting Schizophrenia Drug Revenue by Type (2023-2028) & (USD Million)
Table 127. Middle East & Africa Long-Acting Schizophrenia Drug Revenue by Application (2017-2022) & (USD Million)
Table 128. Middle East & Africa Long-Acting Schizophrenia Drug Revenue by Application (2023-2028) & (USD Million)
Table 129. Middle East & Africa Long-Acting Schizophrenia Drug Revenue by Country (2017-2022) & (USD Million)
Table 130. Middle East & Africa Long-Acting Schizophrenia Drug Revenue by Country (2023-2028) & (USD Million)
LIST OF FIGURES
Figure 1. Long-Acting Schizophrenia Drug Picture
Figure 2. Global Long-Acting Schizophrenia Drug Revenue Market Share by Type in 2021
Figure 3. Oral
Figure 4. Injection
Figure 5. Long-Acting Schizophrenia Drug Revenue Market Share by Application in 2021
Figure 6. Hospital Picture
Figure 7. Pharmacies Picture
Figure 8. Other Picture
Figure 9. Global Long-Acting Schizophrenia Drug Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 10. Global Long-Acting Schizophrenia Drug Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Long-Acting Schizophrenia Drug Revenue Market Share by Region (2017-2028)
Figure 12. Global Long-Acting Schizophrenia Drug Revenue Market Share by Region in 2021
Figure 13. North America Long-Acting Schizophrenia Drug Revenue (USD Million) and Growth Rate (2017-2028)
Figure 14. Europe Long-Acting Schizophrenia Drug Revenue (USD Million) and Growth Rate (2017-2028)
Figure 15. Asia-Pacific Long-Acting Schizophrenia Drug Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. South America Long-Acting Schizophrenia Drug Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Middle East and Africa Long-Acting Schizophrenia Drug Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Long-Acting Schizophrenia Drug Market Drivers
Figure 19. Long-Acting Schizophrenia Drug Market Restraints
Figure 20. Long-Acting Schizophrenia Drug Market Trends
Figure 21. Johnson & Johnson Recent Developments and Future Plans
Figure 22. Teva Recent Developments and Future Plans
Figure 23. Eli Lilly Recent Developments and Future Plans
Figure 24. Bristol Myers Squibb Recent Developments and Future Plans
Figure 25. AstraZeneca Recent Developments and Future Plans
Figure 26. Sumitomo Dainippon Pharma Recent Developments and Future Plans
Figure 27. Allergan Recent Developments and Future Plans
Figure 28. Novartis Recent Developments and Future Plans
Figure 29. Cardinal Health Recent Developments and Future Plans
Figure 30. Sun Pharmaceutical Industries Recent Developments and Future Plans
Figure 31. GlaxoSmithKline Recent Developments and Future Plans
Figure 32. Sanis Health Recent Developments and Future Plans
Figure 33. Qilu Pharmaceutical Recent Developments and Future Plans
Figure 34. Otsuka Pharmaceutical Recent Developments and Future Plans
Figure 35. Vanda Pharmaceuticals Recent Developments and Future Plans
Figure 36. H.Lundbeck Recent Developments and Future Plans
Figure 37. Organon Recent Developments and Future Plans
Figure 38. Hansoh Recent Developments and Future Plans
Figure 39. Hengrui Recent Developments and Future Plans
Figure 40. Nhwa Group Recent Developments and Future Plans
Figure 41. Yangtze River Pharmaceutical Group Recent Developments and Future Plans
Figure 42. Global Long-Acting Schizophrenia Drug Revenue Share by Players in 2021
Figure 43. Long-Acting Schizophrenia Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 44. Global Top 3 Players Long-Acting Schizophrenia Drug Revenue Market Share in 2021
Figure 45. Global Top 10 Players Long-Acting Schizophrenia Drug Revenue Market Share in 2021
Figure 46. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 47. Global Long-Acting Schizophrenia Drug Revenue Share by Type in 2021
Figure 48. Global Long-Acting Schizophrenia Drug Market Share Forecast by Type (2023-2028)
Figure 49. Global Long-Acting Schizophrenia Drug Revenue Share by Application in 2021
Figure 50. Global Long-Acting Schizophrenia Drug Market Share Forecast by Application (2023-2028)
Figure 51. North America Long-Acting Schizophrenia Drug Sales Market Share by Type (2017-2028)
Figure 52. North America Long-Acting Schizophrenia Drug Sales Market Share by Application (2017-2028)
Figure 53. North America Long-Acting Schizophrenia Drug Revenue Market Share by Country (2017-2028)
Figure 54. United States Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Canada Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Mexico Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Europe Long-Acting Schizophrenia Drug Sales Market Share by Type (2017-2028)
Figure 58. Europe Long-Acting Schizophrenia Drug Sales Market Share by Application (2017-2028)
Figure 59. Europe Long-Acting Schizophrenia Drug Revenue Market Share by Country (2017-2028)
Figure 60. Germany Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. France Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. United Kingdom Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Russia Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Italy Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Asia-Pacific Long-Acting Schizophrenia Drug Sales Market Share by Type (2017-2028)
Figure 66. Asia-Pacific Long-Acting Schizophrenia Drug Sales Market Share by Application (2017-2028)
Figure 67. Asia-Pacific Long-Acting Schizophrenia Drug Revenue Market Share by Region (2017-2028)
Figure 68. China Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Japan Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. South Korea Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. India Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Southeast Asia Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Australia Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South America Long-Acting Schizophrenia Drug Sales Market Share by Type (2017-2028)
Figure 75. South America Long-Acting Schizophrenia Drug Sales Market Share by Application (2017-2028)
Figure 76. South America Long-Acting Schizophrenia Drug Revenue Market Share by Country (2017-2028)
Figure 77. Brazil Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Argentina Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. Middle East and Africa Long-Acting Schizophrenia Drug Sales Market Share by Type (2017-2028)
Figure 80. Middle East and Africa Long-Acting Schizophrenia Drug Sales Market Share by Application (2017-2028)
Figure 81. Middle East and Africa Long-Acting Schizophrenia Drug Revenue Market Share by Country (2017-2028)
Figure 82. Turkey Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 83. Saudi Arabia Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 84. UAE Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 85. Methodology
Figure 86. Research Process and Data Source
Figure 1. Long-Acting Schizophrenia Drug Picture
Figure 2. Global Long-Acting Schizophrenia Drug Revenue Market Share by Type in 2021
Figure 3. Oral
Figure 4. Injection
Figure 5. Long-Acting Schizophrenia Drug Revenue Market Share by Application in 2021
Figure 6. Hospital Picture
Figure 7. Pharmacies Picture
Figure 8. Other Picture
Figure 9. Global Long-Acting Schizophrenia Drug Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 10. Global Long-Acting Schizophrenia Drug Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Long-Acting Schizophrenia Drug Revenue Market Share by Region (2017-2028)
Figure 12. Global Long-Acting Schizophrenia Drug Revenue Market Share by Region in 2021
Figure 13. North America Long-Acting Schizophrenia Drug Revenue (USD Million) and Growth Rate (2017-2028)
Figure 14. Europe Long-Acting Schizophrenia Drug Revenue (USD Million) and Growth Rate (2017-2028)
Figure 15. Asia-Pacific Long-Acting Schizophrenia Drug Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. South America Long-Acting Schizophrenia Drug Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Middle East and Africa Long-Acting Schizophrenia Drug Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Long-Acting Schizophrenia Drug Market Drivers
Figure 19. Long-Acting Schizophrenia Drug Market Restraints
Figure 20. Long-Acting Schizophrenia Drug Market Trends
Figure 21. Johnson & Johnson Recent Developments and Future Plans
Figure 22. Teva Recent Developments and Future Plans
Figure 23. Eli Lilly Recent Developments and Future Plans
Figure 24. Bristol Myers Squibb Recent Developments and Future Plans
Figure 25. AstraZeneca Recent Developments and Future Plans
Figure 26. Sumitomo Dainippon Pharma Recent Developments and Future Plans
Figure 27. Allergan Recent Developments and Future Plans
Figure 28. Novartis Recent Developments and Future Plans
Figure 29. Cardinal Health Recent Developments and Future Plans
Figure 30. Sun Pharmaceutical Industries Recent Developments and Future Plans
Figure 31. GlaxoSmithKline Recent Developments and Future Plans
Figure 32. Sanis Health Recent Developments and Future Plans
Figure 33. Qilu Pharmaceutical Recent Developments and Future Plans
Figure 34. Otsuka Pharmaceutical Recent Developments and Future Plans
Figure 35. Vanda Pharmaceuticals Recent Developments and Future Plans
Figure 36. H.Lundbeck Recent Developments and Future Plans
Figure 37. Organon Recent Developments and Future Plans
Figure 38. Hansoh Recent Developments and Future Plans
Figure 39. Hengrui Recent Developments and Future Plans
Figure 40. Nhwa Group Recent Developments and Future Plans
Figure 41. Yangtze River Pharmaceutical Group Recent Developments and Future Plans
Figure 42. Global Long-Acting Schizophrenia Drug Revenue Share by Players in 2021
Figure 43. Long-Acting Schizophrenia Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 44. Global Top 3 Players Long-Acting Schizophrenia Drug Revenue Market Share in 2021
Figure 45. Global Top 10 Players Long-Acting Schizophrenia Drug Revenue Market Share in 2021
Figure 46. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 47. Global Long-Acting Schizophrenia Drug Revenue Share by Type in 2021
Figure 48. Global Long-Acting Schizophrenia Drug Market Share Forecast by Type (2023-2028)
Figure 49. Global Long-Acting Schizophrenia Drug Revenue Share by Application in 2021
Figure 50. Global Long-Acting Schizophrenia Drug Market Share Forecast by Application (2023-2028)
Figure 51. North America Long-Acting Schizophrenia Drug Sales Market Share by Type (2017-2028)
Figure 52. North America Long-Acting Schizophrenia Drug Sales Market Share by Application (2017-2028)
Figure 53. North America Long-Acting Schizophrenia Drug Revenue Market Share by Country (2017-2028)
Figure 54. United States Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Canada Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Mexico Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Europe Long-Acting Schizophrenia Drug Sales Market Share by Type (2017-2028)
Figure 58. Europe Long-Acting Schizophrenia Drug Sales Market Share by Application (2017-2028)
Figure 59. Europe Long-Acting Schizophrenia Drug Revenue Market Share by Country (2017-2028)
Figure 60. Germany Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. France Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. United Kingdom Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Russia Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Italy Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Asia-Pacific Long-Acting Schizophrenia Drug Sales Market Share by Type (2017-2028)
Figure 66. Asia-Pacific Long-Acting Schizophrenia Drug Sales Market Share by Application (2017-2028)
Figure 67. Asia-Pacific Long-Acting Schizophrenia Drug Revenue Market Share by Region (2017-2028)
Figure 68. China Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Japan Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. South Korea Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. India Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Southeast Asia Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Australia Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South America Long-Acting Schizophrenia Drug Sales Market Share by Type (2017-2028)
Figure 75. South America Long-Acting Schizophrenia Drug Sales Market Share by Application (2017-2028)
Figure 76. South America Long-Acting Schizophrenia Drug Revenue Market Share by Country (2017-2028)
Figure 77. Brazil Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Argentina Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. Middle East and Africa Long-Acting Schizophrenia Drug Sales Market Share by Type (2017-2028)
Figure 80. Middle East and Africa Long-Acting Schizophrenia Drug Sales Market Share by Application (2017-2028)
Figure 81. Middle East and Africa Long-Acting Schizophrenia Drug Revenue Market Share by Country (2017-2028)
Figure 82. Turkey Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 83. Saudi Arabia Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 84. UAE Long-Acting Schizophrenia Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 85. Methodology
Figure 86. Research Process and Data Source
